Wedbush Analysts Increase Earnings Estimates for argenex

argenex SE (NASDAQ:ARGX) – Equities researchers at Wedbush boosted their Q4 2025 earnings per share (EPS) estimates for argenex in a research report issued to clients and investors on Friday, November 14th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $6.48 for the quarter, up from their previous forecast of $6.15. Wedbush currently has a “Outperform” rating and a $1,000.00 target price on the stock. The consensus estimate for argenex’s current full-year earnings is $3.13 per share. Wedbush also issued estimates for argenex’s Q1 2026 earnings at $7.36 EPS, Q2 2026 earnings at $8.16 EPS, Q3 2026 earnings at $8.95 EPS, Q4 2026 earnings at $9.60 EPS, FY2026 earnings at $34.10 EPS, FY2027 earnings at $46.09 EPS and FY2028 earnings at $61.81 EPS.

A number of other equities research analysts also recently issued reports on ARGX. Stifel Nicolaus set a $882.00 target price on shares of argenex in a research report on Thursday, September 18th. Evercore ISI raised their target price on argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Royal Bank Of Canada upped their price target on argenex from $850.00 to $860.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. Finally, Deutsche Bank Aktiengesellschaft lowered argenex from a “buy” rating to a “hold” rating in a report on Thursday, September 11th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $885.94.

argenex Price Performance

NASDAQ ARGX opened at $907.98 on Monday. The firm has a market capitalization of $55.90 billion, a price-to-earnings ratio of 38.99, a price-to-earnings-growth ratio of 0.93 and a beta of 0.45. The company has a 50 day simple moving average of $799.34 and a 200-day simple moving average of $672.81. argenex has a 52-week low of $510.05 and a 52-week high of $914.87.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $4.40 EPS for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.07 billion. argenex had a return on equity of 29.78% and a net margin of 41.58%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ARGX. Wellington Management Group LLP grew its position in argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after buying an additional 324,653 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of argenex by 570.3% during the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares in the last quarter. Millennium Management LLC increased its position in shares of argenex by 316.9% during the first quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock valued at $158,977,000 after purchasing an additional 204,180 shares during the period. Adage Capital Partners GP L.L.C. raised its stake in shares of argenex by 114.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 297,113 shares of the company’s stock valued at $163,775,000 after purchasing an additional 158,476 shares in the last quarter. Finally, Franklin Resources Inc. raised its stake in shares of argenex by 103.9% in the second quarter. Franklin Resources Inc. now owns 279,803 shares of the company’s stock valued at $154,233,000 after purchasing an additional 142,606 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.